LXRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LXRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Lexicon Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-0.20.
During the past 3 years, the average EPS without NRI Growth Rate was 22.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Lexicon Pharmaceuticals was 27.90% per year. The lowest was -29.10% per year. And the median was 10.35% per year.
For the Biotechnology subindustry, Lexicon Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Lexicon Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Lexicon Pharmaceuticals (NAS:LXRX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Philippe Amouyal | director | C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016 |
Lonnel Coats | director, officer: President and CEO | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Raymond Debbane | director, 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Thomas Garner | officer: SVP, Chief Commercial Officer | 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381 |
Jeffrey L Wade | officer: EVP, Gen. Counsel | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Wendy Mcdermott | officer: VP, Human Resources | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Diane E. Sullivan | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Artal International S.c.a. | director, 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Invus Partners, Llc | director, 10 percent owner | 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022 |
Ulys, Llc | director, 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Kiernan Seth | officer: VP, Chief Commercial Officer | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Kenneth B. Kassler-taub | officer: SVP, Regulatory & QA | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Kristen Alexander | officer: VP, Finance and Accounting | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Craig B Granowitz | officer: SVP, Chief Medical Officer | 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960 |
James F Tessmer | officer: VP, Finance & Acctg | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
From GuruFocus
By Marketwired • 10-09-2023
By GuruFocus Research • 06-21-2023
By sperokesalga sperokesalga • 06-06-2023
By sperokesalga sperokesalga • 05-10-2023
By Marketwired • 09-28-2023
By GlobeNewswire GlobeNewswire • 06-15-2023
By Marketwired • 10-31-2023
By sperokesalga sperokesalga • 06-01-2023
By GlobeNewswire • 11-12-2023
By Marketwired • 06-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.